Global Amiodarone Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Amiodarone Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of irregular heartbeats. This includes ventricular tachycardia (VT), ventricular fibrillation (VF), and wide complex tachycardia, as well as atrial fibrillation and paroxysmal supraventricular tachycardia.
Amiodarone report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Amiodarone market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Cardiac Arrest and Ventricular Tachycardia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Amiodarone industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Amiodarone key manufacturers include Sanofi, Sawai Pharmaceutical, Wyeth Pharmaceuticals(Pfizer), Mylan Pharmaceuticals, Arrow Pharma Pty Ltd, Roemmers, Cipla Pharmaceutical, Shanghai Pharmaceuticals and North China Pharmaceutical Company, etc. Sanofi, Sawai Pharmaceutical, Wyeth Pharmaceuticals(Pfizer) are top 3 players and held % sales share in total in 2022.
Amiodarone can be divided into Tablet Amiodarone, Capsule Amiodarone and Injection Amiodarone,, etc. Tablet Amiodarone is the mainstream product in the market, accounting for % sales share globally in 2022.
Amiodarone is widely used in various fields, such as Cardiac Arrest, Ventricular Tachycardia, Atrial Fibrillation and Others, etc. Cardiac Arrest provides greatest supports to the Amiodarone industry development. In 2022, global % sales of Amiodarone went into Cardiac Arrest filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amiodarone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi
Sawai Pharmaceutical
Wyeth Pharmaceuticals(Pfizer)
Mylan Pharmaceuticals
Arrow Pharma Pty Ltd
Roemmers
Cipla Pharmaceutical
Shanghai Pharmaceuticals
North China Pharmaceutical Company
Harbin Pharmaceutical Group
Segment by Type
Tablet Amiodarone
Capsule Amiodarone
Injection Amiodarone
Cardiac Arrest
Ventricular Tachycardia
Atrial Fibrillation
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Amiodarone market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Amiodarone, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Amiodarone industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Amiodarone in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Amiodarone introduction, etc. Amiodarone Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Amiodarone market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Amiodarone report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Amiodarone market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Cardiac Arrest and Ventricular Tachycardia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Amiodarone industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Amiodarone key manufacturers include Sanofi, Sawai Pharmaceutical, Wyeth Pharmaceuticals(Pfizer), Mylan Pharmaceuticals, Arrow Pharma Pty Ltd, Roemmers, Cipla Pharmaceutical, Shanghai Pharmaceuticals and North China Pharmaceutical Company, etc. Sanofi, Sawai Pharmaceutical, Wyeth Pharmaceuticals(Pfizer) are top 3 players and held % sales share in total in 2022.
Amiodarone can be divided into Tablet Amiodarone, Capsule Amiodarone and Injection Amiodarone,, etc. Tablet Amiodarone is the mainstream product in the market, accounting for % sales share globally in 2022.
Amiodarone is widely used in various fields, such as Cardiac Arrest, Ventricular Tachycardia, Atrial Fibrillation and Others, etc. Cardiac Arrest provides greatest supports to the Amiodarone industry development. In 2022, global % sales of Amiodarone went into Cardiac Arrest filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amiodarone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi
Sawai Pharmaceutical
Wyeth Pharmaceuticals(Pfizer)
Mylan Pharmaceuticals
Arrow Pharma Pty Ltd
Roemmers
Cipla Pharmaceutical
Shanghai Pharmaceuticals
North China Pharmaceutical Company
Harbin Pharmaceutical Group
Segment by Type
Tablet Amiodarone
Capsule Amiodarone
Injection Amiodarone
Segment by Application
Cardiac Arrest
Ventricular Tachycardia
Atrial Fibrillation
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Amiodarone market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Amiodarone, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Amiodarone industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Amiodarone in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Amiodarone introduction, etc. Amiodarone Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Amiodarone market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices